Register for our free email digests:
Division of Pfizer Inc.
Latest From Medivation Inc.
Pfizer needed good news from the Phase III PROSPER trial testing Xtandi in non-metastatic prostate cancer patients to show investors the Medivation deal was worth the cost. It got what it was hoping for.
There’s significant excitement around the potential of PARP inhibitors in the currently established indication of ovarian cancer, but the best is probably yet to come with expansion into other cancers, according to a biopharma advisory firm. This class of drugs is also expected to trigger M&A, putting the spotlight on firms like Tesaro and Clovis Oncology.
Roivant will use the cash to fund other "Vants" that develop drugs or make the process more efficient. Also, Zealand launches its IPO, Apellis raises a $60m Series E and BioMarin tops recent offerings.
CEO Ian Read indicated the company will wait to see if the US tax system is overhauled before completing any large-scale M&A, even as many investors are anxious to see Pfizer make an acquisition.
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Pfizer Inc.
- Senior Management
David T Hung, MD, Pres. & CEO
Jennifer Jarrett, CFO
Joseph Lobacki, Chief Commercial Officer
Marion McCourt, COO
- Contact Info
Phone: (415) 543-3470
525 Market St.
San Francisco, CA 94105
You must sign in to use this functionality
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.